Skip to main content
OpenTrials

Clinical trial condition

Bladder Cancer

Explore clinical trials studying Bladder Cancer. Study availability and eligibility vary by location and protocol.

771 public trials 174 recruiting studies
Refine in advanced search Browse all conditions

Bladder Cancer trial results

Completed

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

NCT05259696

Conditions
Adnexal Diseases, Bladder Cancer, Breast Cancer, +68 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of Southern California Los Angeles, California, United States
  • Stanford Health Care Stanford, California, United States
  • Yale University Cancer Center New Haven, Connecticut, United States
View all 13 locations
View Trial Details
Completed

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

NCT04825834

Conditions
Bladder Cancer, Colonic Diseases, Colorectal Cancer, +48 more
Locations
  • Central Alabama Research Homewood, Alabama, United States
  • Phoenix Medical Group Peoria, Arizona, United States
  • Highlands Oncology Group - Fayetteville Fayetteville, Arkansas, United States
  • Pulmonary Associates of Burlingame Burlingame, California, United States
View all 57 locations
View Trial Details
Completed

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

NCT02903914

Conditions
Adenocarcinoma, Adenoma, Bladder Cancer, +49 more
Locations
  • University of South Alabama Mobile, Alabama, United States
  • Honor Health/Pinnacle Oncology Hematology Scottsdale, Arizona, United States
  • University of Arizona Tucson, Arizona, United States
  • Georgetown Washington D.C., District of Columbia, United States
View all 20 locations
View Trial Details
Completed

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

NCT05524545

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +14 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • Massachusett's General Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • University of North Carolina Chapel Hill, North Carolina, United States
View Trial Details
Completed

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

NCT02553642

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +19 more
Locations
  • University of Connecticut Health Center Farmington, Connecticut, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Westchester Harrison, New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Completed

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

NCT04580485

Conditions
Adenocarcinoma, Adnexal Diseases, Bladder Cancer, +59 more
Locations
  • Cedars-Sinai Medical Center West Hollywood, California, United States
  • University of Maryland-Greenebaum Cancer Center Baltimore, Maryland, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
View all 27 locations
View Trial Details

Related conditions